ReviewGynecology and pelvic medicine2026
Gynecologic management of cervical cancer patients undergoing immunotherapy: an up-to-date narrative review.
Review in Gynecology and pelvic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Cervical cancer (CC) remains a significant global health challenge, especially in low and middle-income countries. The advent of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, has introduced promising therapeutic options for advanced and recurrent cases. However, gynecologic management during immunotherapy is poorly characterized, particularly regarding structured pre-treatment evaluation, integrated oncology-gynecology surveillance, timed contraception and fertility preservation, management of immune-mediated genital-tract fistulas (GTFs), and evidence-based approaches to pregnancy planning and endocrine dysfunction. This narrative review synthesizes evidence on gynecologic management of CC patients receiving immunotherapy, clinical decision frameworks, and identifies knowledge gaps requiring further investigation. Methods: A structured search was performed in PubMed, Web of Science, and the Cochrane Library (January 2015-October 2025) using MeSH terms and keywords for cervical cancer, immunotherapy, ICIs, gynecologic management, and fertility or pregnancy. Only original articles, case reports, guidelines, and reviews in English or Spanish were included. References were supplemented by artificial intelligence (AI)-based retrieval using SciSpace, OpenEvidence, and Perplexity Pro; deduplication ensured AI-derived citations were only retained as "AI-supplementary" when not present in database searches. ChatGPT-5 Thinking was applied solely for English translation and technical editing, with no generative content added to scientific findings. Key Content and Findings: While ICIs (e.g., nivolumab, pilinumab, tisotumab, pembrolizumab, cemiplimab) have improved outcomes for advanced or metastatic CC, specific guidance for gynecologic management remains limited. Findings show that standard gynecologic screenings [human papillomavirus (HPV), cytology] proceed unchanged but should be aligned with oncology visits. Fertility preservation, via oocyte/embryo cryopreservation, and highly effective contraception are essential before, during, and after therapy. ICIs are discouraged during pregnancy; if pregnancy is detected, treatment should be interrupted. Proactive surveillance for immune-related adverse events (irAEs), including the emerging risk of GTF is crucial, especially within the first 6-8 weeks. Conclusions: Immunotherapy advances care for recurrent/metastatic CC but gynecologic management remains insufficiently addressed. Evidence for fertility counseling, reproductive monitoring, and managing gynecologic irAEs is fragmented. This review underscores the need for interdisciplinary oncology-gynecology coordination, clearer practice protocols, and future research focused on women of reproductive age undergoing ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.